CN115175684A - 视网膜下高反射病灶或伴有视网膜下高反射病灶的视网膜疾病的治疗剂 - Google Patents

视网膜下高反射病灶或伴有视网膜下高反射病灶的视网膜疾病的治疗剂 Download PDF

Info

Publication number
CN115175684A
CN115175684A CN202180012792.2A CN202180012792A CN115175684A CN 115175684 A CN115175684 A CN 115175684A CN 202180012792 A CN202180012792 A CN 202180012792A CN 115175684 A CN115175684 A CN 115175684A
Authority
CN
China
Prior art keywords
aptamer
therapeutic agent
subretinal
nucleotide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180012792.2A
Other languages
English (en)
Chinese (zh)
Inventor
中村义一
藤原将寿
优素福·阿里
丹尼·佩里拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribomic Inc
Original Assignee
Ribomic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribomic Inc filed Critical Ribomic Inc
Publication of CN115175684A publication Critical patent/CN115175684A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180012792.2A 2020-02-06 2021-02-05 视网膜下高反射病灶或伴有视网膜下高反射病灶的视网膜疾病的治疗剂 Pending CN115175684A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970842P 2020-02-06 2020-02-06
US62/970,842 2020-02-06
PCT/JP2021/004215 WO2021157681A1 (ja) 2020-02-06 2021-02-05 網膜下高反射病巣または網膜下高反射病巣を伴う網膜疾患の治療剤

Publications (1)

Publication Number Publication Date
CN115175684A true CN115175684A (zh) 2022-10-11

Family

ID=77199348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180012792.2A Pending CN115175684A (zh) 2020-02-06 2021-02-05 视网膜下高反射病灶或伴有视网膜下高反射病灶的视网膜疾病的治疗剂

Country Status (7)

Country Link
US (1) US20230065106A1 (https=)
EP (1) EP4122471A4 (https=)
JP (1) JPWO2021157681A1 (https=)
KR (1) KR20220137699A (https=)
CN (1) CN115175684A (https=)
TW (1) TWI868308B (https=)
WO (1) WO2021157681A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US20050043220A1 (en) * 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
EP2535410A4 (en) * 2010-02-12 2014-08-13 Ribomic Inc APTAMER FOR FGF2 AND USE THEREOF
WO2013186857A1 (ja) * 2012-06-12 2013-12-19 株式会社リボミック Ｆｇｆ２に対するアプタマー及びその使用
CA2943772C (en) * 2014-03-24 2022-07-19 Ribomic Inc. Aptamer for fgf2 and use thereof
US11123411B2 (en) * 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
ES2992308T3 (es) 2018-06-29 2024-12-11 Ribomic Inc Preparación de aptámero

Also Published As

Publication number Publication date
TWI868308B (zh) 2025-01-01
EP4122471A4 (en) 2025-02-19
EP4122471A1 (en) 2023-01-25
TW202142240A (zh) 2021-11-16
US20230065106A1 (en) 2023-03-02
KR20220137699A (ko) 2022-10-12
WO2021157681A1 (ja) 2021-08-12
JPWO2021157681A1 (https=) 2021-08-12

Similar Documents

Publication Publication Date Title
JP2024075637A (ja) 眼科症状を処置するまたは予防するための方法
KR102240217B1 (ko) 근긴장성 이영양증의 치료용 펩티드-결합 모르폴리노 안티센스 올리고뉴클레오티드
US9828601B2 (en) Compositions for inhibiting checkpoint gene expression and uses thereof
JP2022528725A (ja) 筋ジストロフィーを治療するための組成物
JP2020503010A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
JP7834686B2 (ja) アポリポタンパク質（ａ）発現の調節
JP2011529703A (ja) アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体８発現の調節
JP2011529501A (ja) アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体９発現の調節
US10933081B2 (en) Myostatin iRNA compositions and methods of use thereof
JP2011529704A (ja) アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体３発現の調節
JP2024519451A (ja) 筋ジストロフィーのための治療法
JP2021521794A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
PT1877070E (pt) Utilização terapêutica de oligonucleótidos anti-sentido tgf-beta2
KR102156324B1 (ko) 핵산 복합체를 유효성분으로 함유하는 혈관신생관련 질환 치료용 약학 조성물
US20240327831A1 (en) Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
JP2011529967A (ja) アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体７発現の調節
CN120957731A (zh) 用于治疗多囊肾病的修饰的寡核苷酸
WO2019143831A1 (en) Compositions and methods for increasing expression of scn2a
EP4088742A2 (en) Composition for preventing or treating macular degeneration, containing cell permeable nucleic acid complex as active ingredient
CN115175684A (zh) 视网膜下高反射病灶或伴有视网膜下高反射病灶的视网膜疾病的治疗剂
CN111225922B (zh) β连环蛋白核酸抑制剂分子
JP2012508013A (ja) アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体５発現の調節
JP2021526807A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
JP7340264B2 (ja) アプタマー製剤
KR20220026197A (ko) 세포 투과성 핵산 복합체를 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination